Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/II, Multi-site, Open-label, Two-part Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of BNT323 in Combination With BNT327 in Participants With Advanced Breast Cancer

Next Previous
Trial Profile

A Phase I/II, Multi-site, Open-label, Two-part Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of BNT323 in Combination With BNT327 in Participants With Advanced Breast Cancer

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 22 Oct 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs BNT 323 (Primary) ; PM-8002 (Primary)
  • Indications Advanced breast cancer; HER2 positive breast cancer; Male breast cancer; Triple negative breast cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors BioNTech

Most Recent Events

  • 04 Aug 2025 According to BioNTech media release, In May, the first patient was dosed in this trial.
  • 11 Jul 2025 Number of treatment arms increased from 7 to 8 by the addition of "Experimental: Part 2 Cohort 4 - Selected dose level of BNT323 + BNT327" arm.
  • 11 Jul 2025 Planned number of patients changed from 320 to 380.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top